In the future, Wanyite will continue to explore innovative diagnosis and treatment solutions based on diversified treatment scenarios, including innovative sepsis management methods, as well as life support functions of important organs such as lungs and liver, to enhance the dialysis and emergency and critical care treatment experience of Chinese patients with leading digital solutions and excellent services. Wanyite innovates the treatment of acute and critical illnesses and launches the innovative next-generation continuous blood purification device PrisMax SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- Today, Vantive, a renal care company to be spun off by Baxter Healthcare, held a launch ceremony for its new generation of continuous blood purification device PrisMax at the 7th China International Import Expo. Mr. Wang Xiaoyu, Vice President of Acute and Critical Care Business in China, and Ms. Liu Ying, Senior Director of Regulatory Affairs and Quality Department in Asia Pacific and China, delivered speeches on behalf of the company's proposed renal care spin-off company. Together with the company's leadership team and strategic partners, they unveiled the device on site and explained the insights of this local initiative in terms of upgrading diagnosis and treatment services, responding to national policies, and improving clinical value. 
As an advocate of the global concept of continuous blood purification and one of the industry leaders, Vanyite has advanced emergency and critical care therapies that can support the treatment of kidneys and other important organs at the same time. Its continuously upgraded PrisMax system can provide multiple therapies at the same time, assist in the management of acute kidney injury and provide important organ support, bringing new treatment hope to patients with life-threatening multiple organ failure.
As the incidence of kidney diseases such as acute kidney injury (AKI) increases year by year, the demand for continuous blood purification equipment in the Chinese market has also shown a rapid growth trend. In order to actively respond to local medical needs, Wanyite has jointly developed an innovative generation of localized continuous blood purification equipment PrisMax with global critical care experts. The system is customized according to Chinese clinical needs and has been locally manufactured. It has the advantages of high dose achievement, less treatment interruption, and fast machine operation. It will also bring better clinical personalized treatment to patients with acute kidney injury. While achieving precise treatment, it simplifies the workflow of clinical medical care and helps improve the comprehensive operational efficiency of ICU and renal departments. 
At the launch ceremony, Wanyite introduced PrisMax's multiple application scenarios and treatment plans in detail through the PrisMax booth and the "Smart" PrisMax opening video show in China. In addition, the localization of PrisMax in China also requires a strong alliance with Chinese strategic partners. Wanyite, together with Sinopharm China Medical Devices Co., Ltd. and Shanghai Pharmaceuticals Holdings Co., Ltd., will help the localization of PrisMax start its journey, inject strong momentum into the clinical layout, and jointly create Wanyite's integrated commercial solution for acute and critical blood purification, jointly promote the sustainable and high-quality development of China's medical industry, and move towards the vision and goal of "Healthy China 2030".
"Last year, PrisMax made its debut at the 6th CIIE and received widespread attention and expectations. This year, we are very honored to continue to take advantage of the CIIE and announce the launch of PrisMax in China." Wang Xiaoyu, Vice President of Acute and Critical Care Business in China for Baxter Healthcare's proposed spin-off renal care company, shared: "After years of deep cultivation in the CRRT industry, Wanyi Acute and Critical Care has achieved epoch-making treatment technologies such as the AN69 series membrane materials and finished replacement fluid series, providing a full-link integrated treatment solution for critically ill patients. We believe that with the continuous efforts of working together with strategic partners, PrisMax will expand the accessibility of therapies, benefit more Chinese doctors and patients, and contribute to the future of multi-organ critical care treatment." 
The launch of the innovative new generation of localized continuous blood purification equipment PrisMax is another key milestone in Wanyite's development in China. In the future, Wanyite will continue to explore innovative diagnosis and treatment solutions based on diversified treatment scenarios, including innovative sepsis management methods, as well as life support functions of important organs such as lungs and liver, to enhance the dialysis and emergency and critical care treatment experience of Chinese patients with leading digital solutions and excellent services.